These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6380408)

  • 41. Lipolytic and adenyl-cyclase-stimulating activity of glucagon 1-6: comparison with glucagon derivatives chemically modified in the 7-29 sequence.
    Jean-Baptiste E; Rizack MA; Epand RM
    Biosci Rep; 1982 Oct; 2(10):819-24. PubMed ID: 7171745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperglucagonemia and altered responsiveness of hepatic adenylate cyclase-adenosine 3',5'-monophosphate system to hormonal stimulation during chronic ingestion of DL-ethionine.
    Craven PA; Derubertis FR
    Biochim Biophys Acta; 1977 Apr; 497(2):415-27. PubMed ID: 192313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The activity of glucagon-stimulated adenylate cyclase from rat liver plasma membranes is modulated by the fluidity of its lipid environment.
    Dipple I; Houslay MD
    Biochem J; 1978 Jul; 174(1):179-90. PubMed ID: 697751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of the trinitrophenylation of the amino groups of glucagon on its conformational properties and on its ability to activate rat liver adenylyl cyclase.
    Epand RM; Wheeler GE
    Biochim Biophys Acta; 1975 May; 393(1):236-46. PubMed ID: 237568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noncooperative receptor interactions of glucagon and eleven analogues: inhibition of adenylate cyclase.
    England RD; Jenkins WT; Flanders KC; Gurd RS
    Biochemistry; 1983 Mar; 22(7):1722-8. PubMed ID: 6303393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
    Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
    Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1013-23. PubMed ID: 6323532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Semisynthetic glucagon derivatives for structure-function studies.
    Hruby VJ; Wright DE; Lin MC; Rodbell M
    Metabolism; 1976 Nov; 25(11 Suppl 1):1323-5. PubMed ID: 185491
    [No Abstract]   [Full Text] [Related]  

  • 49. Binding of a glucagon photoaffinity label to rat liver plasma membranes and its effect on adenylate cyclase activity before and after photolysis.
    Demoliou-Mason C; Epand RM
    Biochemistry; 1982 Apr; 21(9):1989-96. PubMed ID: 7093224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1004-12. PubMed ID: 6323531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relation of predicted structure to observed conformation and activity of glucagon analogs containing replacements at positions 19, 22, and 23.
    Murphy J; Zhang WJ; Macaulay W; Fasman G; Merrifield RB
    J Biol Chem; 1987 Dec; 262(36):17304-12. PubMed ID: 3693354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iodoglucagon. Preparation and characterization.
    Desbuquois B
    Eur J Biochem; 1975 May; 53(2):569-80. PubMed ID: 1140201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
    Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase.
    Hoosein NM; Gurd RS
    FEBS Lett; 1984 Dec; 178(1):83-6. PubMed ID: 6094259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects.
    Livingston JN; Einarsson K; Backman L; Ewerth S; Arner P
    J Clin Invest; 1985 Feb; 75(2):397-403. PubMed ID: 2982913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activities of deglycosylated thyrotropin at the thyroid membrane receptor-adenylate cyclase system.
    Amr S; Menezez-Ferreira M; Shimohigashi Y; Chen HC; Nisula B; Weintraub BD
    J Endocrinol Invest; 1985 Dec; 8(6):537-41. PubMed ID: 3009595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The adenylate cyclase activity of isolated hepatocytes actions of glucagon and sodium fluoride.
    Crooke MJ; Sneyd JG
    Biochim Biophys Acta; 1980 Aug; 631(1):40-8. PubMed ID: 7397247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of glucagon activation of adenylate cyclase in the presence of Mn2+.
    Houslay MD; Heyworth CM; Whetton AD
    FEBS Lett; 1983 May; 155(2):311-6. PubMed ID: 6303847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Roles of aspartic acid 15 and 21 in glucagon action: receptor anchor and surrogates for aspartic acid 9.
    Unson CG; Wu CR; Merrifield RB
    Biochemistry; 1994 Jun; 33(22):6884-7. PubMed ID: 8204623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.